Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | SNCA | P37840 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SQLE | Q14534 | 3/20 | 0.32 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.32 |
| ▸ | CDC25B | P30305 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8908025 | 1.00 | KDM1A (0.49) | KDM1APTPN1ALOX15PTGS1PDE4A | |
| SCHEMBL15821739 | 1.00 | KDM1A (0.49) | KDM1APTPN1ALOX15PTGS1PDE4A | |
| SCHEMBL15823839 | 0.97 | KDM1A (0.54) | KDM1APTPN1ALOX15KMT2ASQLE | |
| SCHEMBL15823843 | 0.97 | KDM1A (0.54) | KDM1APTPN1ALOX15KMT2ASQLE | |
| SCHEMBL20421286 | 0.97 | KDM1A (0.54) | KDM1APTPN1ALOX15KMT2ASQLE | |
| SCHEMBL15822340 | 0.94 | PTPN1 (0.56) | KDM1APTPN1ALOX15PTGS1PDE4A | |
| SCHEMBL15821746 | 0.94 | PTPN1 (0.56) | KDM1APTPN1ALOX15PTGS1PDE4A | |
| SCHEMBL15822806 | 0.94 | PTPN1 (0.56) | KDM1APTPN1ALOX15PTGS1PDE4A | |
| SCHEMBL20677648 | 0.94 | PTPN1 (0.56) | KDM1APTPN1ALOX15PTGS1PDE4A | |
| SCHEMBL17260202 | 0.94 | PTPN1 (0.56) | KDM1APTPN1ALOX15PTGS1PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2935177-B1 | (6R,10R)-6,10,14-TRIMETYLPENTADECAN-2-ONE PREPARED FROM 6,10-DIMETYLUNDEC-5-EN-2-ONE OR 6,10-DIMETYLUNDECA-5,9-DIEN-2-ONE | DSM IP ASSETS BV (NL) | 2019-07-24 | — | — | EP | disclosed |
| EP-2935189-B1 | USING MIXTURES OF E/Z ISOMERS TO OBTAIN QUANTITATIVELY SPECIFIC PRODUCTS BY COMBINING ASYMMETRIC HYDROGENATION AND ISOMERIZATION | DSM IP ASSETS BV (NL) | 2019-06-12 | — | — | EP | disclosed |
| EP-2935233-B1 | PROCESS OF ASYMMETRIC HYDROGENATION OF KETALS AND ACETALS | DSM IP ASSETS BV (NL) | 2019-01-30 | — | — | EP | disclosed |
| EP-2935188-B1 | USING MIXTURES OF E/Z ISOMERS TO OBTAIN QUANTITATIVELY SPECIFIC PRODUCTS BY COMBINED ASYMMETRIC HYDROGENATIONS | DSM IP ASSETS BV (NL) | 2018-08-01 | — | — | EP | disclosed |
| US-9573872-B2 | Using mixtures of E/Z isomers to obtain quantitatively specific products by combining asymmetric hydrogenation and isomerization | DSM IP ASSETS B.V. (NL) | 2017-02-21 | — | — | US | disclosed |
| US-9561989-B2 | Process of asymmetric hydrogenation of ketals and acetals | DSM IP ASSETS B.V. (NL) | 2017-02-07 | — | — | US | disclosed |
| US-9458076-B2 | Using mixtures of E/Z isomers to obtain quantitatively specific products by combined asymmetric hydrogenations | DSM IP ASSETS B.V. (NL) | 2016-10-04 | — | — | US | disclosed |
| US-9452961-B2 | (6R,10R)-6,10,14-trimetylpentadecan-2-one prepared from 6,10-dimetylundec-5-en-2-one or 6,10-dimetylundeca-5,9-dien-2-one | DSM IP ASSETS B.V. (NL) | 2016-09-27 | — | — | US | disclosed |
| US-20160185683-A1 | PROCESS OF ASYMMETRIC HYDROGENATION OF KETALS AND ACETALS | DSM IP ASSETS B.V. (NL) | 2016-06-30 | — | — | US | disclosed |
| US-20160185702-A1 | USING MIXTURES OF E/Z ISOMERS TO OBTAIN QUANTITATIVELY SPECIFIC PRODUCTS BY COMBINING ASYMMETRIC HYDROGENATION AND ISOMERIZATION | DSM IP ASSETS B.V. (NL) | 2016-06-30 | — | — | US | disclosed |
| EP-2935189-A1 | USING MIXTURES OF E/Z ISOMERS TO OBTAIN QUANTITATIVELY SPECIFIC PRODUCTS BY COMBINING ASYMMETRIC HYDROGENATION AND ISOMERIZATION | DSM IP Assets B.V. (NL) | 2015-10-28 | — | — | EP | disclosed |
| EP-2935177-A1 | (6R,10R)-6,10,14-TRIMETYLPENTADECAN-2-ONE PREPARED FROM 6,10-DIMETYLUNDEC-5-EN-2-ONE OR 6,10-DIMETYLUNDECA-5,9-DIEN-2-ONE | DSM IP Assets B.V. (NL) | 2015-10-28 | — | — | EP | disclosed |
| EP-2935188-A1 | USING MIXTURES OF E/Z ISOMERS TO OBTAIN QUANTITATIVELY SPECIFIC PRODUCTS BY COMBINED ASYMMETRIC HYDROGENATIONS | DSM IP Assets B.V. (NL) | 2015-10-28 | — | — | EP | disclosed |
| WO-2014096065-A1 | (6R,10R)-6,10,14-TRIMETYLPENTADECAN-2-ONE PREPARED FROM 6,10-DIMETYLUNDEC-5-EN-2-ONE OR 6,10-DIMETYLUNDECA-5,9-DIEN-2-ONE | DSM IP ASSETS B.V. (NL) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014096107-A1 | USING MIXTURES OF E/Z ISOMERS TO OBTAIN QUANTITATIVELY SPECIFIC PRODUCTS BY COMBINING ASYMMETRIC HYDROGENATION AND ISOMERIZATION | DSM IP ASSETS B.V. (NL) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014096096-A1 | PROCESS OF ASYMMETRIC HYDROGENATION OF KETALS AND ACETALS | DSM IP ASSETS B.V. (NL) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014096106-A1 | USING MIXTURES OF E/Z ISOMERS TO OBTAIN QUANTITATIVELY SPECIFIC PRODUCTS BY COMBINED ASYMMETRIC HYDROGENATIONS | DSM IP ASSETS B.V. (NL) | 2014-06-26 | — | — | WO | disclosed |
| US-5600015-A | USING RUTHENIUM COMPLEX OF OPTICALLY ACTIVE ATROPISOMERIC DIPHOSPHINE LIGAND AS HYDROGENATION CATALYST | HOFFMANN-LA ROCHE INC. (US) | 1997-02-04 | — | — | US | disclosed |
| EP-0565975-B1 | Process for the preparation of isoprenoid derivatives | HOFFMANN LA ROCHE (CH) | 1996-09-04 | — | — | EP | disclosed |
| EP-0565975-A2 | Process for the preparation of isoprenoid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1993-10-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185702-A1 | USING MIXTURES OF E/Z ISOMERS TO OBTAIN QUANTITATIVELY SPECIFIC PRODUCTS BY COMBINING ASYMMETRIC HYDROGENATION AND ISOMERIZATION | EPHX2, ZDHHC2, GNE | KDM1A 4641/4885PTPN1 4862/4885ALOX15 249/4885 |
| US-20160185683-A1 | PROCESS OF ASYMMETRIC HYDROGENATION OF KETALS AND ACETALS | KAT5, AKR1D1, AKR1C2 | KDM1A 1647/4885PTPN1 4881/4885ALOX15 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.